| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 12, 2023 | Standigm's "Green Ribbon Campaign" to support Mitochondria Disease Awareness Week | SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- On September 5th, 2023 Standigm, a company using artificial intelligence (AI) technology for drug discovery and development launched, the "Green Ribbon Campaign," event to support... |
| Aug 10, 2023 | Standigm and Nashville Biosciences join to revolutionize early drug discovery | Companies will identify novel therapeutic targets using Standigm's explainable AI and Nashville Biosciences' datasets
SEOUL, South Korea, Aug. 10, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technology for dr... |
| Apr 13, 2023 | Standigm Announces Younsung Choo as Chief Executive Officer | Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced that Younsung Choo has been appointed Chief Executive Officer (CEO). As the new CEO of Standigm, Choo will focus primarily on co... |
| Apr 13, 2023 | Standigm announces Younsung Choo as chief executive officer | Former LG life Sciences exec and long-time Standigm advisor brings extensive experience in pharmaceuticals and project management
SEOUL, South Korea, April 13, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) tech... |
| Apr 12, 2023 | Standigm announces Younsung Choo as chief executive officer | Former LG life Sciences exec and long-time Standigm advisor brings extensive experience in pharmaceuticals and project management
SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) tech... |
| Apr 5, 2023 | Standigm and Institut Pasteur Korea Identify Drug Candidates for Resistant Tuberculosis Thanks to Right Foundation Grant | Research achievements enabled by a combination of advanced AI platforms, research capabilities, and drug discovery technologies
SEOUL, South Korea, April 5, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technol... |
| Jan 5, 2023 | Standigm cited as 'Top 10 Generative AI-based startup based on VC Investment, 2019-2021' in Gartner® report | SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, today announced that it had been cited in the 2022 Gartner Emerging Tech: Venture Capital... |
| Nov 30, 2022 | How AI-Based Drug Repurposing Could Help Prevent Repetitive Behavior Disorders | Jinhan Kim, Co-founder and CEO, Standigm
Repetitive behavioral disorders such as obsessive-compulsive disorder (OCD), Tic Disorder and Tourette Syndrome have been challenging to treat because they involve considerable complexity. For exampl... |
| Nov 17, 2022 | Standigm Synthetic Research Center successfully accelerates drug discovery in its first year | Lab uniquely enables collaboration between chemical and AI researchers
SEOUL, South Korea, Nov. 16, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced the celebration of its Synthetic Research Cent... |
| Nov 17, 2022 | Standigm Synthetic Research Center successfully accelerates drug discovery in its first year | Lab uniquely enables collaboration between chemical and AI researchers
SEOUL, South Korea, Nov. 17, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced the celebration of its Synthetic Research Cent... |
| Oct 19, 2022 | STANDIGM TO ATTEND BIO-EUROPE® 2022 | Standigm will present AI-driven drug discovery technology at the conference
CAMBRIDGE, England, Oct. 19, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th a... |
| Sep 7, 2022 | Few-Shot Prediction of Drug-Target Binding Affinities for Small Molecule Drug Discovery, Upcoming Webinar Hosted by Xtalks | Accurate prediction of the binding behavior between the target protein and the compounds is crucial for discovering the candidate molecule with decent potency and selectivity.
TORONTO, Ontario (PRWEB) September 07, 2022
In the early stage o... |
| Aug 18, 2022 | Standigm names Carl Foster chief business officer to expand strategic partnerships for AI drug discovery | Veteran biotech and pharmaceutical executive will help company increase its growth and international impact
SEOUL, South Korea, Aug. 18, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence... |
| Aug 16, 2022 | STANDIGM WINS GOLD AND BRONZE STEVIE® AWARDS IN 2022 INTERNATIONAL BUSINESS AWARDS® | Winners to Be Celebrated During Event in London on 15 October
SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- Standigm was named the winner of a Gold Stevie® Award in the Pharmaceutical category and a Bronze Stevie® Award in the Computer ... |
| Jun 9, 2022 | Standigm Signs MOU with Merck Korea for AI drug Discovery Research | - Merck's retrosynthesis AI software 'SYNTHIA™ retrosynthesis software' accelerates Standigm's synthesis capability
SEOUL, South Korea, June 9, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intel... |
| Jun 1, 2022 | Standigm Signs MOU with Merck Korea for AI drug Discovery Research | - Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability
SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discover... |
| May 17, 2022 | Facilitating Target Identification Processes with AI: Challenges and Prospects, Upcoming Webinar Hosted by Xtalks | Artificial intelligence (AI) has been introduced as a promising tool to handle the abundant data and extract the information efficiently.
TORONTO (PRWEB) May 17, 2022
Target identification has been an important challenge in developing thera... |
| Nov 30, 2021 | Standigm signs MOU with Institut Pasteur Korea for AI-based drug discovery research on infectious disease | SEOUL, South Korea, Nov. 30, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding ("MOU")... |
| Nov 9, 2021 | Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery | Standigm Inc., the leading workflow artificial intelligence drug discovery company, announced that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd , a life science and green chemicals com... |
| Nov 9, 2021 | Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery | SEOUL, South Korea, Nov. 9, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had established a Synthetic Research Center in... |
| Nov 3, 2021 | Standigm Files PCT Patent Application of AI-driven Repurposed Drugs for Primary Mitochondrial Disease | SEOUL, South Korea, Nov. 3, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had filed PCT ("Patent Cooperation Treaty... |
| Aug 20, 2021 | Standigm Expands Global Footprints with New Office in Cambridge, UK | SEOUL, South Korea, Aug. 20, 2021 /PRNewswire/ -- Standigm, a leading workflow AI drug discovery company, today announced the opening of a new office in Cambridge, United Kingdom ("UK"), to accommodate the company's rapid growth i... |
| Jul 6, 2021 | Standigm Secures $10 M From Pavilion Capital to Accelerate Its Global Competitiveness | Standigm Inc. (“Standigm”), the leading workflow artificial intelligence (AI) drug discovery company, announced today that they have secured a $10 million investment from Pavilion Capital, a Singapore-based investment institution. Standigm ... |
| Jul 6, 2021 | Standigm Raises $10M in Funding | Standigm Inc., a Seoul, South Korea-based workflow artificial intelligence (AI) drug discovery company, raised $10m in funding.
Pavilion Capital made the investment.
The company intends to use the funds for the clinical research of AI-drive... |
| Jul 4, 2021 | Standigm Receives Strategic Investment From SK Chemicals | Standigm Inc., a Seoul, South Korea-based workflow artificial intelligence (AI) drug discovery company, received an investment from SK Chemicals Co., Ltd., a life science and green chemicals company.
The amount of the deal was not disclosed... |
| Mar 8, 2021 | Asia Digest: Ryde appoints adviser for 2022 IPO; S Korea’s Standigm secures $44.5m in pre-IPO round | Singapore-based Ryde has appointed SAC Capital as its financial adviser to lead preparations ahead of a planned IPO while Standigm, a South Korean Artificial Intelligence (AI) company for drug discovery, has closed $44.5 million in a pre-IP... |
| Mar 8, 2021 | Asia Digest: Ryde appoints adviser for 2022 IPO; S Korea’s Standigm secures $44.5m in pre-IPO round | Premium
Singapore-based Ryde has appointed SAC Capital as its financial adviser to lead preparations ahead of a planned IPO while Standigm, a South Korean Artificial Intelligence (AI) company for drug discovery, has closed $44.5 million in ... |
| Mar 8, 2021 | Standigm Raises $44.5M in Pre-IPO Funding | Standigm Inc., a Seoul, South Korea-based Artificial Intelligence (AI) company for drug discovery, closed a $44.5m pre-IPO funding round.
The round was co-led by SKS PE and Daishin Private Equity, joined by new investors SKS PE, Daishin Pri... |
| Mar 5, 2021 | Standigm Secures $44.5 M in Pre-IPO Funding Round | Standigm Inc. (“Standigm”), a leading Korean Artificial Intelligence (AI) company for drug discovery, announces today that it has closed $44.5 million in a pre-IPO funding round co-led by SKS PE and Daishin Private Equity. The round was joi... |
| Mar 27, 2019 | South Korea startup Standigm secures $11.5 million Series B to scale its AI-powered drug pipelines toward license-out | Not so many people know what it takes to bring new drug to market. Drugs can take a decade of research and over a billion dollars’ worth of development before they reach the market. Resources are wasted in the pre-discovery phase through a ... |
| Standigm Secures $44.5 M in Pre-IPO Funding Round | SEOUL, South Korea--(BUSINESS WIRE)--Mar 5, 2021--
Standigm Inc. (“Standigm”), a leading Korean Artificial Intelligence (AI) company for drug discovery, announces today that it has closed $44.5 million in a pre-IPO funding round co-led by S... |
